Samples Collected and Shared with a New Collaborator
We are happy to announce that OMF and Scientific Advisory Board member Dr. Robert Naviaux at University of California, San Diego (UCSD), are now collaborating with Director Oliver Fiehn, PhD and his team at the West Coast Metabolomics Center (WCMC), University of California, Davis (UCD).
Metabolomics Validation Study update from Dr. Naviaux:
“We have exceeded our original goal of 110 samples. We have collected 72 samples from females (36 CFS + 36 Controls), and 54 samples from males (28 CFS and 26 Controls). The total in-house is 126 samples. This is a 50% increase in the size of the study from our 84 samples in study #1.”
The aims of the OMF Metabolomics Validation Study are:
1. Biological replication
2. Analytical replication
From UCSD: The biological replication will come from the metabolomic analysis of the independent cohort of patients with ME/CFS using the mass spec methods developed at UCSD as in the first paper. All patients have been collected and testing has commenced. This will take 4-6 months (hopefully sooner).
From UCD: The analytical replication will come from a replicate analysis of the same samples using similar mass spectometry methods running the same tests by Dr. Oliver Fiehn’s team at UCD – OMF has funded this study as well and it will commence in March.
The results from UCD will be compared to the first and second metabolomics study and all should be completed by July. This testing will be blinded without reviewing results from Dr Naviaux’s validation study until completed. Dr. Fiehn will receive de-identified samples and will be using the same methodology. Each test that is tested within Dr Naviaux’s study will be tested in this study on a similar Mass Spectrometer platform.
To support this revolutionary research, please donate today.
About the UC Davis Team:
Director Oliver Fiehn and his team at the West Coast Metabolomics Center (WCMC) are committed to provide research and services conducting research in metabolomic method developments and biomedical applications. Professor Fiehn and his team pioneered developments and applications in metabolomics since 1998 with over 220 publications to date. Professor Fiehn specifically focuses on lipids and primary metabolism in cancer, cardiovascular diseases, diabetes, nutrition and metabolic syndrome projects. The WCMC is dedicated to provide further standardization and higher content in biochemical information through automatic annotation of metabolites and by using a range of chemical and biochemical database identifiers with every report we generate.